Member Info for roses

80k delayed buy from this morning just shown.

Good start to the day, Looks like there is a decent delayed buy due to show up !

Half a million sell just printed at 2.06p

oops 381655 - all buys

380655 - All buys

Some nice big buying this morning and a tick up as well

". At registration, the most common problem identified by the quality control review is insufficient specificity of outcome measures (eg, “safety”). At results reporting, the five most important problems by frequency of occurrence are invalid/inconsistent unit of measure, insufficient information about a scale, internal inconsistencies between different parts of a record, inclusion of written results or conclusions, and unclear baseline, or outcome measure."

Now, no one can say that VAL are manipulating the numbers because they havn't publicly released numbers, any numbers, nada , nothing which is highly unusual !

But a QC review such as this would pick up any such inconsistencies.

woody, from their site, as you can see it is not a clerical review.

quality control review
National Library of Medicine (NLM) staff perform a limited review of submitted study records for apparent errors, deficiencies, or inconsistencies. NLM staff identify potential major and advisory issues and provide comments directly to the study sponsor or investigator. Major issues identified in QC review must be addressed or corrected (see First submitted that met QC criteria and Results first submitted that met QC criteria). Advisory issues are suggestions to help improve the clarity of the record. NLM staff do not verify the scientific validity or relevance of the submitted information. The study sponsor or investigator is responsible for ensuring that the studies follow all applicable laws and regulations.

woody, how do you come to that conclusion ?

surely clerical issues would not be classed as needing to "Address major issues"

The 201 results were initially submitted on AUG 6th 18 and rejected on september 5th 18

I can't see anywhere where it mentions Sep 6th 18 ?

Valju i think most people would consider "address major issues" much more of a problem than just an amendment.

It took 11 months to get the report in in the first place.

https://clinicaltrials.gov/ct2/show/results/NCT02875340?term=VAL401&draw=1&rank=1&view=results

Then click on the info button just above yesterdays submission date

So it seems the UK gov are not happy with the trial results have have sent them back to Valirx yesterday to "address major issues"

either the trial site on the Russian border got them wrong or Val did, either way it doesnt look good.

Thanks mathsprof for digging this info up.

Oh dear, The results were returned back to Valirx dated 5th sep 18 (yesterday) and it states and i quote

"The date on which the National Library of Medicine provided quality control (QC) review comments to the study sponsor or investigator. The sponsor or investigator must address major issues identified in the review comments. "

And they then release todays RNS

Something very, very fishy going on.

The 50k will have been a buy as L2 ticked up immediately after.

12p paid now on NEX 25k

C7 - totally agree.

By the way, I see your red badge is back, Did LSE accidentally reinstate your premium membership ?

delayed buy of 215,000 at 12.5388p (highest trade of the day)

Sorry, you replied to a post in a thread about the last few trades in Scancell and then posted a link on a completely different subject in the same thread. I was struggling to follow the connection ?

Hadn't realised that, although it's never seemed to be too much of a problem before.

Really cant understand why they would take exception to NEX trades as long as you only state the amount and the price it went through at, and not declare it as a buy or sell.

Still can't figure out the relevance of your last link though ?